Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Genvoya Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Genvoya Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for Genvoya in treatment-naive patients or patients switching from a stable antiretroviral regimen while virologically suppressed, subject to age, weight, renal, and clinical eligibility requirements.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGenvoya Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateApr 26, 2016
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, weight, treatment history, viral load, regimen stability, resistance history, and creatinine clearance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12 yearsMinimum age
    ≥35 kgMinimum weight
    <50 copies/mLSuppression threshold
    ≥6 monthsStability period
    ≥30 mL/min

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum CrCl
    DailyDosing

    Coverage Criteria

    Initial Therapy or Replacement Therapy

    Covered when all baseline requirements are met and the patient meets one of the eligible treatment pathways.

    Baseline eligibility: Patient is at least 12 years old, weighs at least 35 kg (77 lb), and has creatinine clearance of at least 30 mL/min.Age ≥12 years; weight ≥35 kg; CrCl ≥30 mL/min

    Hepatic and renal function should be checked before initiation.

    Eligible treatment pathway

    • Initial treatment: Patient has no prior antiretroviral treatment history.Treatment-naive
    • Replacement of current regimen: Patient is virologically suppressed on a stable antiretroviral regimen for at least 6 months, with no history of treatment failure and no known substitutions associated with resistance to Genvoya's individual components.HIV-1 RNA <50 copies/mL; stable regimen ≥6 months

    Nonapproved Use

    Genvoya is not approved for the following uses or patient conditions.

    Nonapproved conditions: Treatment of hepatitis B; HIV-1 and hepatitis B coinfection; Child-Pugh class C hepatic impairment; or creatinine clearance less than 30 mL/min.CrCl <30 mL/min

    These conditions are identified under the policy's nonapproval and precaution statements.

    Genvoya is not approved for hepatitis B treatment, HIV-1 and hepatitis B coinfection, Child-Pugh class C hepatic impairment, or patients with creatinine clearance below 30 mL/min. Hepatic and renal function should be checked before initiating therapy.

    For replacement of a current antiretroviral regimen, the patient must have no history of treatment failure and no known substitutions associated with resistance to Genvoya’s individual components. These requirements apply in addition to virologic suppression and stability on the current regimen.

    Eligibility Thresholds

    Minimum age
    Minimum ageAt least 12 years
    Eligible patientsAdults and pediatric patients 12 years of age and older
    Authorization requirementPatients must meet the minimum age requirement for Genvoya prior authorization
    Minimum weight
    Minimum weightAt least 35 kg (77 lb)
    Eligible patientsAdults and pediatric patients weighing at least 35 kg
    Authorization requirementPatients must meet the minimum weight requirement for Genvoya prior authorization

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Genvoya. Authorization is limited to adults and pediatric patients who meet the age, weight, treatment-history, virologic, resistance, and renal-function criteria below.

    • Patients must be 12 years of age or older and weigh at least 35 kg (77 lb).
    • Eligible use is either initial therapy in a treatment-naïve patient or replacement of a current antiretroviral regimen in a qualifying virologically suppressed patient.
    Documentation Required

    Clinical Eligibility and Laboratory Documentation

    Submit clinical records supporting the requested indication and all eligibility requirements before initiation. The record must establish the patient’s treatment history, virologic status, duration of regimen stability when applicable, resistance history, and renal and hepatic function.

    • For treatment-naïve patients, document that there is no prior antiretroviral treatment history.

    Medication Background

    Genvoya is a fixed-dose combination antiretroviral tablet containing elvitegravir, an HIV-1 integrase strand transfer inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors. It is administered as one tablet once daily with food. TAF provides lower circulating tenofovir levels and higher intracellular levels than tenofovir disoproxil fumarate, a profile noted in the policy in relation to potential liver, kidney, and bone toxicity.

    Policy Definitions

    Treatment-naive
    DefinitionA patient with no prior antiretroviral treatment history
    Eligible pathwayTreatment-naive patients may qualify for initial therapy
    Required baseline criteriaThe patient must also meet the age, weight, and renal requirements
    Virologically suppressed
    HIV-1 RNALess than 50 copies/mL
    Regimen stabilityReceiving a stable antiretroviral regimen for at least 6 months
    Eligible pathwayMay qualify for replacement of the current antiretroviral regimen

    Initial Therapy

    Treatment-Naive Initial Therapy

    Initial therapy is eligible when all patient eligibility requirements are met.

    Treatment-naive eligibility: Patient has no prior antiretroviral treatment history, is at least 12 years old, weighs at least 35 kg (77 lb), and has creatinine clearance of at least 30 mL/min.Age ≥12 years; weight ≥35 kg; CrCl ≥30 mL/min

    Check hepatic and renal function before initiating therapy.

    Replacement of Current Antiretroviral Regimen

    Replacement of Current Antiretroviral Regimen

    Regimen replacement is eligible when all continuation conditions are met.

    Virologically suppressed regimen replacement: Patient is virologically suppressed on a stable antiretroviral regimen for at least 6 months, with no history of treatment failure and no known substitutions associated with resistance to Genvoya's individual components.HIV-1 RNA <50 copies/mL; stable regimen ≥6 months

    Patient must also be at least 12 years old, weigh at least 35 kg (77 lb), and have creatinine clearance of at least 30 mL/min.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGenvoya Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateApr 26, 2016
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, weight, treatment history, viral load, regimen stability, resistance history, and creatinine clearance.
    SourceLink
    On This Page
    Coverage CriteriaEligibility ThresholdsPrior Authorization and DocumentationMedication BackgroundPolicy DefinitionsInitial TherapyReplacement of Current Antiretroviral Regimen
    Virologic suppression
    HIV-1 RNA thresholdLess than 50 copies/mL
    Clinical statusVirologically suppressed
    Applies toReplacement of the current antiretroviral regimen
    Stable antiretroviral regimen
    Required durationAt least 6 months
    RegimenStable antiretroviral regimen
    Applies toPatients replacing the current antiretroviral regimen
    Creatinine clearance
    Minimum CrClAt least 30 mL/min
    AssessmentCreatinine clearance is used to assess renal eligibility
    Nonapproved thresholdCreatinine clearance less than 30 mL/min is not approved
  1. For regimen replacement, document HIV-1 RNA less than 50 copies/mL on a stable antiretroviral regimen for at least 6 months.
  2. Document no history of treatment failure and no known substitutions associated with resistance to Genvoya’s individual components.
  3. Check and submit baseline renal and hepatic function; creatinine clearance must be at least 30 mL/min.
  4. Denial Risk

    Denial-Risk Conditions

    Requests may be denied when the patient does not meet the authorization criteria or when required clinical documentation is absent or contradictory.

    • Age under 12 years or weight under 35 kg (77 lb).
    • Prior antiretroviral treatment when the patient does not qualify for replacement therapy, including failure to demonstrate HIV-1 RNA below 50 copies/mL or stability for at least 6 months.
    • Documented treatment failure or known resistance-associated substitutions to Genvoya’s individual components.
    • Creatinine clearance less than 30 mL/min or missing renal-function documentation.
    Denial Risk

    Nonapproved Clinical Use

    Genvoya is not approved for treatment of chronic hepatitis B and should not be authorized for the excluded clinical conditions identified in the policy.

    • Do not use to treat chronic hepatitis B infection.
    • Not approved for patients coinfected with HIV-1 and hepatitis B.
    • Not approved for patients with Child-Pugh class C hepatic impairment.
    • Do not initiate when creatinine clearance is less than 30 mL/min.
    CrCl
    DefinitionCreatinine clearance (CrCl) is used to assess renal eligibility
    Minimum required valueAt least 30 mL/min
    Eligibility consequencePatients with creatinine clearance less than 30 mL/min are not approved